Welcome to the e-CCO Library!

P663: Switching from Remicade® to biosimilar CT-P13 in inflammatory bowel disease patients: one year follow-up of a prospective observational cohort study
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Smits L.*1, Grelack A.1, Drenth J.1, de Jong D.1, Boshuizen R.2, van Esch A.1, Derikx L.1, Hoentjen F.1

Created: Wednesday, 20 February 2019, 10:36 AM
P663: The effect of vitamin D deficiency, and its correction, on healthcare utilisation among patients with inflammatory bowel disease (IBD)
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

N. Chou1, J. Gubatan2, O. H. Nielsen3, A. Moss*1

Created: Friday, 22 February 2019, 9:41 AM
P664 The impact of vedolizumab on extra-intestinal manifestations in inflammatory bowel disease patients: A real-life experience of a single-centre cohort
Year: 2020
Source:

ECCO'20 Vienna

Authors:

M. TRUYENS1,2,3, J. Geldof1, G. Dewitte1, E. Glorieus1, G. Varkas2,4, D. Elewaut2,4, T. Lobaton Ortega1,3

Created: Thursday, 30 January 2020, 10:12 AM
P664: Adherence to mesalazine and identification of patients with ulcerative colitis in healthcare administrative databases of Tuscany (Italy)
Year: 2021
Source: ECCO'21 Virtual
Authors: Bertani, L.(1);Bartolini, C.(2);Ferraro, S.(3);Convertino, I.(3);Giometto, S.(3);Tillati, S.(3);Valdiserra, G.(3);Cappello, E.(3);Blandizzi, C.(3);Lucenteforte, E.(3);Gini, R.(2);Tuccori, M.(3,4);Costa, F.(5);
Created: Wednesday, 2 June 2021, 4:12 PM
P664: Analysis of Clinical Trial Screen Failures in IBD: Real World Results from the IOIBD
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Vieujean, S.(1)*;Lindsay, J.O.(2,3);Rubin, D.(4);D'Amico, F.(5,6);Ahuja, V.(7);Silverberg, M.S.(8);Sood, A.(9);Yamamoto-Furusho, J.K.(10);Nagahori, M.(11);Watanabe, M.(12);Koutroubakis, I.E.(13);Foteinogiannopoulou, K.(13);Walsh, A.(14);Outtier, A.(15);Abreu, M.T.(16);Dubinsky, M.(17);Siegel, C.(18);Louis, E.(1);Dotan, I.(19);Reinisch, W.(20);Danese, S.(5);Peyrin-Biroulet, L.(21);
Created: Friday, 14 July 2023, 11:12 AM
P664: Association between pharmacologic loss of response profile of anti-TNF and clinical outcome with vedolizumab
Year: 2018
Source: ECCO '18 Vienna
Authors:

J. Berthaux1, P. DeBoissieu1, A. Amiot2, T. Vaysse1, F. Carbonnel1, M. Collins1*

Created: Thursday, 21 February 2019, 9:14 AM
P664: SB5 and reference adalimumab show cross-immunogenicity in patients with inflammatory bowel disease or rheumatoid arthritis
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

J. Gonçalves*1, G. Myung2, E. Hong2, M. Park2, D. Jeong2, J. Ghil2

Created: Friday, 22 February 2019, 9:41 AM
P664: The transitioning healthcare economy of IBD: changes in resource allocation over time
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Spizzo P.

Created: Wednesday, 20 February 2019, 10:36 AM
P665 Which second-line biologic after anti-TNF failure during Crohn’s disease: Ustekinumab or vedolizumab, a multicentre retrospective study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

C. Rayer1, X. Roblin2, D. Laharie3, B. Caron4, M. Flamant5, M. Dewitte1, M. Fumery6, S. Viennot7, A. Bourreille8, B. Pariente9, L. Siproudhis1, L. Peyrin-Biroulet10, G. Bouguen1

Created: Thursday, 30 January 2020, 10:12 AM
P665: 1-Year clinical and endoscopic follow-up of vedolizumab therapy in refractory PIBD patients
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

M. M. E. Jongsma*1, M. A. Aardoom1, L. de Ridder1, J. C. Escher1

Created: Friday, 22 February 2019, 9:41 AM
P665: Cardiovascular risk profile in chronic auto-inflammatory diseases: a cross-sectional single center study
Year: 2021
Source: ECCO'21 Virtual
Authors: Sleutjes, J.A.M.(1);Roeters van Lennep , J.E.(2);Verploegh , P.J.P.(1);van Doorn , M.B.A.(3);Vis , M.(4);van der Woude , C.J.(1);de Vries , A.C.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P665: Higher BMI but not systemic immune suppression increases the risk of short-term postoperative complications in Crohn’s disease patients
Year: 2018
Source: ECCO '18 Vienna
Authors:

D. Podmanicky1*, V. Bak1, M. Krizko2, Z. Zelinkova2

Created: Thursday, 21 February 2019, 9:14 AM
P665: Social Media Listening to better Understand the Lived Experience of Individuals With Ulcerative Colitis
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Auriat, O.(1);Lucats, L.(1)*;Badalamenti, S.(2);Kruger, A.(2);Wiekowski, M.(2);Glotfelty, L.(2);Van Hoogstraten, H.(3);Coulouvrat, C.(4);
Created: Friday, 14 July 2023, 11:12 AM
P665: Towards FAIR longitudinal IBD registries: preliminary results of an iterative design process of a reusable and interoperable IBD database model
Year: 2022
Source: ECCO'22
Authors: Adriaans , G.M.C.(1,2);Hendrix , E.M.B.(1,2);Creemers , R.(2,3);Janssen , L.(1,2);Demers , K.(1,2);Rezazadeh Ardabili , A.(1,2);Jonkers , D.M.A.E.(1,2);Pierik , M.J.(1,2);
Created: Friday, 11 February 2022, 3:56 PM
P665: Unchanged infliximab serum concentrations after switching from the reference infliximab to the biosimilar CT-P13 in patients with quiescent Crohn's disease: a prospective study
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Strik A.*1, van de Vrie W.2, van Megen Y.3, Bloemsaat-Minekus J.3, Rispens T.4, D'Haens G.1

Created: Wednesday, 20 February 2019, 10:36 AM
P666 Neutropenia in inflammatory bowel disease patients on TNF inhibitors: A single-centre, retrospective cohort study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

D. AlAskar, A. Mais, E. Al Sulais, T. Alameel

Created: Thursday, 30 January 2020, 10:12 AM
P666: Effect of anastomotic configuration on Crohn's Disease recurrence after primary ileocolic resection. A comparative monocentric study of end-to-end versus side-to-side anastomosis.
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Bislenghi, G.(1);Vancoillie, P.J.(1)*;Fieuws, S.(2);Verstockt, B.(3);Sabino, J.(4);Wolthuis, A.(1);D'Hoore, A.(1);
Created: Friday, 14 July 2023, 11:12 AM
P666: Frequency and outcome of SARS-CoV2 infection in patients with inflammatory bowel disease on different biological therapy
Year: 2021
Source: ECCO'21 Virtual
Authors: Resál, T.(1);Farkas, K.(1);Molnár, T.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P666: Long-term effectiveness and safety of vedolizumab (VDZ) in inflammatory bowel disease (IBD): Results from the Spanish ENEIDA Registry
Year: 2018
Source: ECCO '18 Vienna
Authors:

M. Chaparro1,2,3,4*, A. Garre1,2,3,4, I. Alfaro4,5, M. Iborra4,6, P. Mesonero7, I. Vera Mendoza8, A. Rodríguez9, J. Miquel-Cusachs10, S. Riestra11, P. Navarro12, L. De Castro Parga13, C. González-Muñoza14, M. Rivero Tirado15, M. Mañosa4,16, L. Fernández Salazar17, M. García-Sepulcre18, J. Guardiola19, J. Cabriada20, A. Gutiérrez Casbas4,21, B. Sicilia22, J.L. Pérez Calle23, M. Piqueras24, I. Guerra25, O. Roncero26, M. Navarro-Llavat27, E. Sainz28, J. Barrio29, X. Calvet4,30, A. García31, M. Llorente Barrio32, R. Lorente33, P. Almela34, R. Madrigal35, A.J. Lucendo Villarín36, R. Pajares37, M. Van Domselaar38, J. Legido Gil39, J.P. Gisbert1,2,3,4

Created: Thursday, 21 February 2019, 9:14 AM